You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ER-positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Assessed by 18F-FES PET/CT in MBC With ER-positive Primary Tumor

Recruiting
  • Breast Cancer
    • Shanghai, Shanghai, China
      Biyun Wang, MD
    Apr 5, 2023

    Estrogen Receptor Positive Breast Cancer Trial in Edmonton (Estradiol)

    Active, not recruiting
    • Estrogen Receptor Positive Breast Cancer
    • Edmonton, Alberta, Canada
      Cross Cancer Institute
    Feb 1, 2023

    HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving

    Completed
    • Breast Neoplasms
    • NET or NCT
    • Haidian, Beijing, China
      Peking University Cancer Hospital
    Dec 30, 2022

    Breast Cancer Trial (Giredestrant, Giredestrant plus triptorelin, Anastrozole plus triptorelin)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jun 13, 2023

    ER+ HER2- Advanced Breast Cancer Trial in Chuo-ku, Kashiwa, Koto-ku (AZD9833)

    Active, not recruiting
    • ER+ HER2- Advanced Breast Cancer
    • Chuo-ku, Japan
    • +2 more
    Jan 24, 2023

    Breast Cancer, Triple Negative Breast Cancer Trial in Gothenburg (Imatinib 400 MG Oral Tablet)

    Not yet recruiting
    • Breast Cancer
    • Triple Negative Breast Cancer
    • Imatinib 400 MG Oral Tablet
    • Gothenburg, Sweden
      Barbro Linderholm
    Feb 1, 2023

    Gut and Tumor Microbiome in Advanced ER-positive and

    Not yet recruiting
    • Breast Cancer
    • Melanoma
    • Observation
    • (no location specified)
    Nov 6, 2023

    Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based

    Not yet recruiting
    • Breast Cancer
    • Cancer of the Breast
    • VENTANA MIB-1 Ki67 assay
    • +4 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Apr 18, 2023

    Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,

    Recruiting
    • Premenopausal Breast Cancer
    • +2 more
    • Taipei City, Taiwan
      Department of Oncology, National Taiwan University Hospital
    Feb 7, 2023

    Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)

    Completed
    • Breast Neoplasms
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Oct 26, 2022

    Breast Cancer Trial in Boston, Danvers (Ribociclib, Endocrine therapy)

    Recruiting
    • Breast Cancer
    • Boston, Massachusetts
    • +2 more
    Jan 6, 2023

    Older Women With ER Positive, HER2 Negative Early Breast Cancer

    Enrolling by invitation
    • Breast Cancer Female
    • Translational study
    • Sutton, United Kingdom
      The Royal Marsden NHS Foundation Trust
    Feb 8, 2023

    Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)

    Not yet recruiting
    • Breast Cancer
    • Ovarian Function Suppression + Aromatase Inhibitor
    • Adjuvant Chemotherapy + Ovarian Function Suppression
    • (no location specified)
    May 19, 2023

    ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

    Recruiting
    • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
    • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
    • Montpellier, France
    • +1 more
    Nov 16, 2022

    ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer Trial in Luoyang, Shanghai (TFX06 tablet)

    Recruiting
    • ER+, HER2- Advanced Breast Cancer
    • Metastatic Breast Cancer
    • TFX06 tablet
    • Luoyang, Henan, China
    • +1 more
    Jun 25, 2023

    ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer Trial in Madison, Milwaukee (Onapristone, Fulvestrant)

    Recruiting
    • ER-positive Breast Cancer
    • +2 more
    • Madison, Wisconsin
    • +1 more
    Jul 7, 2022

    Breast Cancer, ER Positive Breast Cancer Trial in Lebanon (Letrozole 2.5mg)

    Recruiting
    • Breast Cancer
    • ER Positive Breast Cancer
    • Letrozole 2.5mg
    • Lebanon, New Hampshire
    • +1 more
    Dec 19, 2022

    Advanced or Metastatic Breast Cancer Trial in Paris (Milademetan, Patient Reported Outcomes (PROs) and Health-Related Quality of

    Not yet recruiting
    • Advanced or Metastatic Breast Cancer
    • Milademetan
    • Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
    • Paris, France
      Institut Curie
    Jun 27, 2023

    Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (OP-1250, Fulvestrant, Anastrozole)

    Not yet recruiting
    • Breast Cancer
    • +4 more
    • (no location specified)
    Aug 31, 2023

    ER-Positive Breast Cancer, HER2-negative Breast Cancer Trial in Houston (Fulvestrant Run-In, No Fulvestrant Run-In)

    Recruiting
    • ER-Positive Breast Cancer
    • HER2-negative Breast Cancer
    • Fulvestrant Run-In
    • No Fulvestrant Run-In
    • Houston, Texas
      Houston Methodist Cancer Center
    Mar 23, 2022

    Breast Cancer Trial in Beijing (18F-FES PET/CT scan)

    Recruiting
    • Breast Cancer
    • 18F-FES PET/CT scan
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Nov 4, 2022

    Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

    Active, not recruiting
    • Breast Neoplasms
    • Chuo Ku, Japan
    • +1 more
    Dec 19, 2022

    ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer Trial (Elacestrant, Tamoxifen, Letrozole 2.5mg)

    Not yet recruiting
    • ER-positive Breast Cancer
    • +3 more
    • (no location specified)
    Aug 22, 2022

    TNBC - Triple-Negative Breast Cancer Trial (Alkaline Glucosodiene Molecules)

    Not yet recruiting
    • TNBC - Triple-Negative Breast Cancer
    • Alkaline Glucosodiene Molecules
    • (no location specified)
    Jul 14, 2023

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

    Not yet recruiting
    • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
    • (no location specified)
    Sep 26, 2023